“…Second, clonidine has consistently shown greater side effects compared with both guanfacine and lofexidine in terms of orthostatic hypotension, sexual dysfunction and withdrawal syndrome following cessation, (Gish, Miller, Honey, & Johnson, 2010; Sorkin & Heel, 1986). In addition, guanfacine has been shown to enhance selective executive and inhibitory control processes underlying impulsivity and other behavioral factors associated with outcome in substance abuse (Brady, Gray, & Tolliver, 2011; Sofuoglu, DeVito, Waters, & Carroll, 2013) in non-human primates (Franowicz & Arnsten, 2002), healthy volunteers (Jakala, Riekkinen, Sirvio, Koivisto, Kejonen, et al, 1999; Jakala, Riekkinen, Sirvio, Koivisto, & Riekkinen, 1999) and other clinical populations (Swartz, McDonald, Patel, & Torgersen, 2008). Conversely, although few studies assessing the cognitive profile of lofexidine have been conducted, one study documented decreased cognitive efficiency after lofexidine administration compared with placebo, in fourteen opioid dependent individuals stabilized on methadone (Schroeder et al, 2007).…”